These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37888092)

  • 1. Urinary Liver-Type Fatty Acid Binding Protein, a Biomarker for Disease Progression, Dialysis and Overall Mortality in Chronic Kidney Disease.
    Mitsides N; Mitra V; Saha A; Harris S; Kalra PA; Mitra S
    J Pers Med; 2023 Oct; 13(10):. PubMed ID: 37888092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary liver-type fatty acid-binding protein in clinically healthy elderly cats: Evaluation of its potential to detect IRIS stage 1 chronic kidney disease and borderline proteinuria.
    Kongtasai T; Paepe D; Mortier F; Marynissen S; Meyer E; Duchateau L; Daminet S
    Vet Med Sci; 2023 Jan; 9(1):3-12. PubMed ID: 36418182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver-type fatty acid-binding protein and neutrophil gelatinase-associated lipocalin in cats with chronic kidney disease and hyperthyroidism.
    Kongtasai T; Meyer E; Paepe D; Marynissen S; Smets P; Mortier F; Demeyere K; Vandermeulen E; Stock E; Buresova E; Defauw P; Duchateau L; Daminet S
    J Vet Intern Med; 2021 May; 35(3):1376-1388. PubMed ID: 33723886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
    Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
    Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.
    Fujita D; Takahashi M; Doi K; Abe M; Tazaki J; Kiyosue A; Myojo M; Ando J; Fujita H; Noiri E; Sugaya T; Hirata Y; Komuro I
    Heart Vessels; 2015 May; 30(3):296-303. PubMed ID: 24554034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease.
    Watanabe A; Ohata K; Oikawa T; Sugaya T; Miyazaki M; Satoh H; Katayama M
    Can J Vet Res; 2021 Apr; 85(2):156-160. PubMed ID: 33883825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart-Type Fatty Acid Binding Protein, Cardiovascular Outcomes, and Death: Findings From the German CKD Cohort Study.
    Schneider MP; Schmid M; Nadal J; Wanner C; Krane V; Floege J; Saritas T; Busch M; Sitter T; Friedrich N; Stockmann H; Meiselbach H; Nauck M; Kronenberg F; Eckardt KU;
    Am J Kidney Dis; 2022 Oct; 80(4):483-494.e1. PubMed ID: 35288215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease.
    Katayama M; Ohata K; Miyazaki T; Katayama R; Wakamatsu N; Ohno M; Yamashita T; Oikawa T; Sugaya T; Miyazaki M
    J Vet Intern Med; 2020 Mar; 34(2):761-769. PubMed ID: 32087614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial.
    Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Kimura K
    J Lab Clin Med; 2005 Mar; 145(3):125-33. PubMed ID: 15871303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.
    Xie Y; Xue W; Shao X; Che X; Xu W; Ni Z; Mou S
    PLoS One; 2014; 9(11):e112865. PubMed ID: 25402279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.
    Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Omata M; Kimura K
    Mol Cell Biochem; 2006 Mar; 284(1-2):175-82. PubMed ID: 16532260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis.
    Mou S; Wang Q; Li J; Shi B; Ni Z
    Clin Chim Acta; 2012 Jan; 413(1-2):187-91. PubMed ID: 21958699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary Biomarkers Can Predict Weaning From Acute Dialysis Therapy in Critically Ill Patients.
    Pan HC; Huang TT; Huang CT; Sun CY; Chen YM; Wu VC
    Arch Pathol Lab Med; 2022 Nov; 146(11):1353-1363. PubMed ID: 35311928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevation of Urinary Liver-Type Fatty Acid-Binding Protein Is a Harbinger of Poor Patient Prognosis after Allogeneic Stem Cell Transplantation.
    Shingai N; Ota A; Kato K; Kondo K; Sadaga Y; Kato C; Sakai S; Kambara Y; Nabe Y; Asano K; Teshima K; Kurihara K; Ouchi F; Fujiwara H; Shimabukuro M; Inai K; Jinguji A; Toya T; Shimizu H; Najima Y; Kobayashi T; Sugaya T; Ando M; Doki N
    Transplant Cell Ther; 2024 Jan; 30(1):121.e1-121.e8. PubMed ID: 37813188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression.
    Ying T; Clayton P; Naresh C; Chadban S
    BMC Nephrol; 2018 Mar; 19(1):55. PubMed ID: 29514605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine liver fatty acid binding protein and chronic kidney disease progression.
    Khatir DS; Bendtsen MD; Birn H; Nørregaard R; Ivarsen P; Jespersen B; Buus NH
    Scand J Clin Lab Invest; 2017 Nov; 77(7):549-554. PubMed ID: 28745927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD.
    Matsui K; Kamijo-Ikemori A; Imai N; Sugaya T; Yasuda T; Tatsunami S; Toyama T; Shimizu M; Furuichi K; Wada T; Shibagaki Y; Kimura K
    Clin Exp Nephrol; 2016 Apr; 20(2):195-203. PubMed ID: 26189083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Urinary Protein-to-Creatinine Ratio and Chronic Kidney Disease Progression: A Secondary Analysis of a Prospective Cohort Study.
    Qin X; Hu H; Cen J; Wang X; Wan Q; Wei Z
    Front Med (Lausanne); 2022; 9():854300. PubMed ID: 35433766
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.